nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2006-10-4-18-22nefr-693Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПЛЕОТРОПНЫЕ КАРДИОПРОТЕКТИВНЫЕ ЭФФЕКТЫ ЭРИТРОПОЭТИНАPLEOTROPIC CARDIOPROTECTIVE EFFECTS OF ERYTHROPOIETINШутовА. М.ShutovA. M.

кафедра терапии и профессиональных болезней и кафедра фармакологии с курсом клинической фармакологии медицинского фа­культета

СаенкоЮ. В.SaenkoYu. V.

кафедра терапии и профессиональных болезней и кафедра фармакологии с курсом клинической фармакологии медицинского фа­культета

Ульяновский государственный университет, г. УльяновскRussian Federation2006100420061041822Copyright © Шутов А.М., Саенко Ю.В., 20062006Шутов А.М., Саенко Ю.В.Shutov A.M., Saenko Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/693

.

.

анемияинфаркт миокардахроническая болезнь почекхроническая сердечная недостаточностьэритропоэтинanemiachronic kidney diseaseerythropoietinheart chronic failuremyocardial infarctionReferencesKoury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71(2):524-527Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71(2):524-527Koury ST, Bondurant MC, Koury MJ, Semenza G. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77(11):2497-2503Koury ST, Bondurant MC, Koury MJ, Semenza G. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77(11):2497-2503Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998;13[suppl]:23-27Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998;13[suppl]:23-27Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998;13 [suppl 2]: 3–8Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998;13 [suppl 2]: 3–8Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100 (20):11612-11617Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100 (20):11612-11617Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteineproteases. Circulation 2002; 106 (23): 2973–2979Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteineproteases. Circulation 2002; 106 (23): 2973–2979Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99(4):2258-2263Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99(4):2258-2263Brines M, Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70(2):246-250Brines M, Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70(2):246-250Miki T, Miura T, Yano T et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006;317(1):68-75Miki T, Miura T, Yano T et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006;317(1):68-75Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt8):1281-1283Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt8):1281-1283Fisher J W. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003;228(1):1–14Fisher J W. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003;228(1):1–14Schwartzenberg S, Ben-Shoshan J, Keren G et al. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Expert Rev Cardiovasc Ther 2006; 4(1): 41-50Schwartzenberg S, Ben-Shoshan J, Keren G et al. The role of erythropoietin in myocardial protection: potential mechanisms and applications. Expert Rev Cardiovasc Ther 2006; 4(1): 41-50Joyeux-Faure M, Ramond A, Beguin PC et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 2006;20(1):51-56Joyeux-Faure M, Ramond A, Beguin PC et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 2006;20(1):51-56Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther2005;19(5):333-336Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther2005;19(5):333-336George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner.Cardiovasc Res 2005;68(2):299-306George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner.Cardiovasc Res 2005;68(2):299-306Akimoto T, Kusano E, Inaba T et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000; 58(1):269–282Akimoto T, Kusano E, Inaba T et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000; 58(1):269–282Jaquet K, Krause K, Tawakol-Khodai M et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64(2):326–333Jaquet K, Krause K, Tawakol-Khodai M et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64(2):326–333Carlini RG, Alonzo EJ, Dominguez J et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55(2):546–553Carlini RG, Alonzo EJ, Dominguez J et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55(2):546–553Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47(3):740–745Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47(3):740–745Hirata A, Minamino T, Asanuma H et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48(1):176-184Hirata A, Minamino T, Asanuma H et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48(1):176-184Horl WH, Ertl G. Anaemia and the heart. Eur J Clin Invest 2005;35 [Suppl 3]:20-25Horl WH, Ertl G. Anaemia and the heart. Eur J Clin Invest 2005;35 [Suppl 3]:20-25Xu B, Dong GH, Liu H et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 2005; 35(2):161-168Xu B, Dong GH, Liu H et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 2005; 35(2):161-168Guijarro C, Egido J. Transcription factor kappa B (NF-кB) and renal disease. Kidney Int 2001;59(2):415-424Guijarro C, Egido J. Transcription factor kappa B (NF-кB) and renal disease. Kidney Int 2001;59(2):415-424Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316(3): 999-1005Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316(3): 999-1005Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 2005;46(2):211-215Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 2005;46(2):211-215van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46(1):125-133van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46(1):125-133Spandou E, Tsouchnikas I, Karkevelas G et al. Erythropoietin attenuated renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006;21(2):330-336Spandou E, Tsouchnikas I, Karkevelas G et al. Erythropoietin attenuated renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006;21(2):330-336Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signalling cascades. Nature 2001;412(6847):641–647Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signalling cascades. Nature 2001;412(6847):641–647Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308(4):990–994Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308(4):990–994Rafiee P, Shi Y, Su J et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100 (3): 187-197Rafiee P, Shi Y, Su J et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100 (3): 187-197Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22(5):503-514Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22(5):503-514Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63(2):208-216Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63(2):208-216Guglin ME, Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 2006;14(4):200-204Guglin ME, Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 2006;14(4):200-204Tada H, Kagaya Y, Takeda M et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006;71(3):466-477Tada H, Kagaya Y, Takeda M et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006;71(3):466-477Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005;42(5-6):233-241Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005;42(5-6):233-241Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation2003;108(1):79–85Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation2003;108(1):79–85Olea FD, Vera Janavel G et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol2006;47(6):736-741Olea FD, Vera Janavel G et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol2006;47(6):736-741Li Y, Takemura G, Okada H et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71 (4):684-694Li Y, Takemura G, Okada H et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71 (4):684-694Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113(4):535-453Li L, Takemura G, Li Y et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113(4):535-453Noiri E, Nagano N, Negishi K et al. Efficacy of Darbepoetin in Doxorubicin-Induced Cardiorenal Injury in Rats. Nephron Exp Nephrol 2006;104(1):e6-e14Noiri E, Nagano N, Negishi K et al. Efficacy of Darbepoetin in Doxorubicin-Induced Cardiorenal Injury in Rats. Nephron Exp Nephrol 2006;104(1):e6-e14Саенко ЮВ, Шутов АМ, Напалкова СМ, Селиванова ОС. Эритропоэтин снижает проявления оксидативного стресса, индуцированного доксорубицином, в почках крыс. Нефрология2005;9(2):96-100Саенко ЮВ, Шутов АМ, Напалкова СМ, Селиванова ОС. Эритропоэтин снижает проявления оксидативного стресса, индуцированного доксорубицином, в почках крыс. Нефрология2005;9(2):96-100Lewis BS, Karkabi B, Jaffe R et al. Anaemia and heart failure: statement of the problem. Nephrol Dial Transplant 2005; 20 [Suppl 7]:3-6Lewis BS, Karkabi B, Jaffe R et al. Anaemia and heart failure: statement of the problem. Nephrol Dial Transplant 2005; 20 [Suppl 7]:3-6Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775-1780Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775-1780Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2):294-299Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2):294-299Silverberg DS, Wexler D, Iaina A et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38 (2): 295-310Silverberg DS, Wexler D, Iaina A et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38 (2): 295-310Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;(9)3:7-15Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;(9)3:7-15George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestiv heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165(11):1304-1309George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestiv heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165(11):1304-1309Wexler D, Silverberg D, Blum M et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant 2005;20 [Suppl 7]:11-15Wexler D, Silverberg D, Blum M et al. Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant 2005;20 [Suppl 7]:11-15Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004;19[Suppl 2]Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004;19[Suppl 2]Пересмотренные Европейские рекомендации по оптимальной практике лечения анемии у пациентов с хронической почечной недостаточностью. Анемия 2005;3:6-60Пересмотренные Европейские рекомендации по оптимальной практике лечения анемии у пациентов с хронической почечной недостаточностью. Анемия 2005;3:6-60Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002;61[Suppl 80]:35–38Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002;61[Suppl 80]:35–38Hampl H, Hennig L, Rosenberger C et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25(3):211-220Hampl H, Hennig L, Rosenberger C et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25(3):211-220Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35(2):250–256Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35(2):250–256Manolis AS, Tzeis S, Triantafyllou K et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(5):355-375Manolis AS, Tzeis S, Triantafyllou K et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(5):355-375Kirkpantur A, Kahraman S, Yilmaz R et al. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters. Artif Organs 2005;29(12):965-972Kirkpantur A, Kahraman S, Yilmaz R et al. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters. Artif Organs 2005;29(12):965-972Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46(5):799-811Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46(5):799-811Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16(7):2180-2189Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16(7):2180-2189Coussons PJ, Baig S, Fanutti C, Grant R. Novel tissue remodelling roles for human recombinant erythropoietin. Biochem Soc Trans 2005;33(5):1129-1130Coussons PJ, Baig S, Fanutti C, Grant R. Novel tissue remodelling roles for human recombinant erythropoietin. Biochem Soc Trans 2005;33(5):1129-1130Anton Martinez J, Ojeda Ortego J, Gonzalez Blanco P et al. Increased levels of erythropoietin in the initial phase of acute myocardial infarction. An Med Interna 1997;14(9):459-461Anton Martinez J, Ojeda Ortego J, Gonzalez Blanco P et al. Increased levels of erythropoietin in the initial phase of acute myocardial infarction. An Med Interna 1997;14(9):459-461Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45(9):1406-1412Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45(9):1406-1412Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20 (2):135-141Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20 (2):135-141Shin DH, Kwon YI, Choi SI et al. Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: report of two cases. Basic Clin Pharmacol Toxicol 2006; 98 (2): 222-224Shin DH, Kwon YI, Choi SI et al. Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: report of two cases. Basic Clin Pharmacol Toxicol 2006; 98 (2): 222-224Vasu S, Kelly P, Lawson WE. Anemia in heart failure-a concise review. Clin Cardiol 2005;28(10):454-458Vasu S, Kelly P, Lawson WE. Anemia in heart failure-a concise review. Clin Cardiol 2005;28(10):454-458

The authors declare that there are no conflicts of interest present.